The incidental mammogram finding isn’t a reason to panic, but it might a reason to make sure other risk factors are under ...

The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...